Sotera Health (SHC) Stock: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$18.37
0.11 (0.60%)
▲
5d:
-3.47%
30d:
-2.75%
90d:
+12.08%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SHC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SHC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.40
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$15.15
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $18.37, which is considered oversold relative to its 30-day fair value range of $18.42 to $19.29. The stock's valuation (Forward PE: 17.1) is in line with its historical norms (16.5). At these levels, the market is pricing in 1.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is currently testing key support at $18.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SHC scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.72 (+23.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is currently testing key support at $18.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SHC scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.72 (+23.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$18.42 -
$19.29
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (18/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.7% below Wall St target ($22.72)
- NEUTRAL: Market pricing in 1.3% annual earnings growth - fairly valued
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$18.42 -
$19.29
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$18.01
Resistance Level
$19.45
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.09
Wall Street Target
$22.72
(+23.7%)
Revenue Growth (YoY)
9.2%
Earnings Growth (YoY)
569.5%
Profit Margin
13.4%
Valuation Premium vs History
+1.3% premium
PE vs Historical
17.1 vs 16.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.3%
(market-implied from PE analysis)
1-Year Target
$18.61
(+1%)
2-Year Target
$18.85
(+3%)
3-Year Target
$19.10
(+4%)
3-Yr Target (if PE normalizes)
(PE: 17→17)
PE COMPRESSION
$18.44
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 9.2%)
$28.21
(+54%)
Base:
(SPY PE: 17.1, Growth: 9.2%)
$23.90
(+30%)
Bear:
(PE: 14.5, Growth: 9.2%)
$20.32
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 32.04 | Current EPS (TTM): $0.57
Bull Case
$37.88
(+106%)
Analyst growth 88.6%, PE expands to 35.2
Base Case
$34.43
(+87%)
Market implied 88.6%, PE stable at 32.0
Bear Case
$12.42
(-32%)
Severe decline -20.0%, PE contracts to 27.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 5:33 PM ET
Data refreshes hourly during market hours. Next update: 6:33 PM
Data refreshes hourly during market hours. Next update: 6:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$638 | 51 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$229 | 49 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 49 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$338 | 47 HOLD |
